|
|||||
|
|
Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? |
|
| Authors: | Pierre Tiberghien Xavier de Lamballerie Pascal Morel Pierre Gallian Karine Lacombe Yazdan Yazdanpanah |
| Institution: | 1. Etablissement Français du Sang, La Plaine-St Denis, France;2. IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France;3. Etablissement Français du Sang, La Plaine-St Denis, France
UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon, France;4. Etablissement Français du Sang, La Plaine-St Denis, France IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France;5. Sorbonne Université Inserm IPLESP Hôpital St Antoine AP-HP, Paris, France;6. REACTing Inserm, Paris, France AP-HP Hôpital Bichat, Paris, France |
| Abstract: | Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality. |
| Keywords: | antibody convalescent plasma COVID-19 infectious disease plasma |